Best of ASCO 2024, Boise

Boise, ID US
July 13, 2024 to July 14, 2024

This CME-accredited oncology conference, Best of ASCO 2024, Boise, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2024 ASCO® Annual Meeting (ASCO2024) in June 2024. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2024 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

ORGANIZING COMMITTEE: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Christos Vaklavas, MD - Huntsman Cancer Institute of the University of Utah

Andrew S. Pierson, MD - St. Alphonsus Regional Medical Center

HOTEL INFORMATION

A limited number of rooms have been booked at the Grove Hotel at a discounted nightly rate of $219 per room for this conference's attendees and sponsors. Please book your room at this link here by June 10th, 2024.

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2024 and discuss their application in clinical settings

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 10.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.00 Contact Hours.
Course opens: 
04/11/2024
Course expires: 
10/31/2024
Event starts: 
07/13/2024 - 7:00am PDT
Event ends: 
07/14/2024 - 4:00pm PDT
Cost:
$350.00

DAY 1 - JULY 13th, 2024


All times below are listed in Mountain Time (MT).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:20 AM – 09:50 AM  Session 1 - Hematologic Malignancies

Session Chair: Christos Vaklavas, MD

08:20 AM – 08:50 AM  MDS/Leukemias - Jacob Appelbaum, MD, PhD

08:50 AM – 09:20 AM  Multiple Myeloma - Amandeep Godara, MD

09:20 AM – 09:50 AM  Lymphoma & CLL - Solomon Graf, MD


09:50 AM – 10:20 AM  Break & Exhibits


10:20 AM – 11:50 AM  Session 2 - Thoracic Oncology

Session Chair: Sri Tella, MD

10:20 AM – 10:50 AM  Early-Stage NSCLC - Matthew Gumbleton, MD

10:50 AM – 11:20 AM  Metastatic NSCLC - Lei Deng, MD

11:20 AM – 11:50 AM  Small Cell Lung Cancer - Rafael Santana-Davila, MD


11:50 AM – 12:50 PM  Lunch & Exhibits


12:50 PM – 02:30 PM  Session 3 - Case-Based Presentations 1

Session Chair: Andrew Scott Pierson, MD

12:50 PM – 01:15 PM  Case 1: Sarcoma - Anna Chalmers, MD

01:15 PM – 01:40 PM  Case 2: Brain Tumor Updates - Vyshak Venur, MD

01:40 PM – 02:05 PM  Case 3: Head and Neck Cancer - Katie Kerrigan, DO

02:05 PM – 02:30 PM  Case 4: Palliative Care/Supportive Therapy - Wesley Jones, DO


02:30 PM – 03:00 PM  Break & Exhibits


03:00 PM – 04:30 PM  Session 4 - Genitourinary Cancer 

Session Chair: Ian Qureshi, DO

03:00 PM – 03:30 PM  Prostate Cancer - Umang Swami, MD

03:30 PM – 04:00 PM  Kidney Cancer - Benjamin Maughan, MD, PharmD

04:00 PM – 04:30 PM  Bladder Cancer - Umang Swami, MD 


DAY 2 - JULY 14th, 2024
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 09:00 AM  Session 5 - Case-Based Presentations 2

Session Chair: Andrew Scott Pierson, MD

08:00 AM – 08:30 AM  Case 1: GI Cancer - Nicholas Gorden, MD

08:30 AM – 09:00 AM  Case 2: Breast Cancer - Mei Wei, MD


09:00 AM – 10:30 AM  Session 6 - GI Cancer

Session Chair: Leila Khaddour, MD

09:00 AM – 09:30 AM  Colorectal Cancer - Andrew Coveler, MD

09:30 AM – 10:00 AM  Hepatobiliary and Pancreatic Malignancies - Ignacio Garrido-Laguna, MD, PhD, MBA

10:00 AM – 10:30 AM  Upper GI Cancer - Chris Nevala-Plagemann, MD, MSCI


10:30 AM – 10:45 AM  Break & Exhibits


10:45 AM – 12:15 PM  Session 7 - Breast Cancer

Session Chair: Stephanie Hodson, MD

10:45 AM – 11:15 AM  Hormone Receptor Positive Breast Cancer - Christos Vaklavas, MD

11:15 AM – 11:45 AM  HER2 Positive Breast Cancer - Mei Wei, MD

11:45 AM – 12:15 PM  Triple Negative Breast Cancer - Namita Chittoria, MD


12:15 PM  Adjourn

The Grove Hotel
245 S Capitol Blvd
Boise, ID 83702
United States

A limited number of rooms have been booked at the Grove Hotel at a discounted nightly rate of $219 per room for this conference's attendees and sponsors. Please book your room at this link here by June 10th, 2024.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

Organizing Committee

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Christos Vaklavas, MD - Huntsman Cancer Institute of the University of Utah

Andrew S. Pierson, MD - St. Alphonsus Regional Medical Center

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Conference Chair(s)

Andrew Pierson, MD

has no relevant financial relationships to disclose at this time.

Christos Vaklavas, M.D., Associate Professor

has a financial relationship (Financial Support) with CytomX;.
has a financial relationship (Employment) with Flatiron;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with H3 Biomedicine;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Financial Support) with SeaGen;.
Session Chair(s)

Stephanie Hodson, MD

has a financial relationship (Independent contractor) with PRIME;.
has a financial relationship (Independent contractor) with PRIME;.

Leila Khaddour, Medical Oncology

has no relevant financial relationships to disclose at this time.

Ian Qureshi

has no relevant financial relationships to disclose at this time.

Sri Harsha Tella, MD FACP

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Jacob Appelbaum, MD/PhD

has no relevant financial relationships to disclose at this time.

Namita Chittoria, MD

has a financial relationship (Professional Services) with Gilead Sciences ;.

Andrew Coveler, MD

has a financial relationship (Travel) with Nucana;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Seagen/Pfizer;.
has a financial relationship (Independent contractor) with Actuate;.
has a financial relationship (Independent contractor) with AbGenomics;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Astrazeneneca;.

Lei Deng, MD

has a financial relationship (Travel) with MJH Life Sciences;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Bristol Meyer Squibb;.
has a financial relationship (Other) with MJH Life Sciences;.

Ignacio Garrido-Laguna

has a financial relationship (Grant Or Contract) with Tango Therapeutics;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with MedImmune;.
has a financial relationship (Grant Or Contract) with Revolution Medicine;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with ABM Therapeutics;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline ;.
has a financial relationship (Grant Or Contract) with Sotio;.
has a financial relationship (Grant Or Contract) with BridgeBio Pharma , Genentech;.
has a financial relationship (Grant Or Contract) with Sumitomo;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Genentech;.

Amandeep Godara, MD

has a financial relationship (Other) with Janssen;.

Solomon Graf, MD

has a financial relationship (Grant Or Contract) with BeiGene;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Genetech;.
has a financial relationship (Grant Or Contract) with Acerta Pharma;.

Matthew Gumbleton, MD, PhD

has a financial relationship (Independent contractor) with OMNI Health Media;.
has a financial relationship (Independent contractor) with MJH Lifesciences ;.
has a financial relationship (Patent) with Alterna Therapeutics;.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer Oncology;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Peloton Therapeutis;.

Christopher Nevala-Plagemann, MD, MSCI

has no relevant financial relationships to disclose at this time.

Rafael Santana-Davila, MD

has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Aztra-Zeneca;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Astellas Pharma;.
has a financial relationship (Professional Services) with Mirati Therapeutics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Monte Rosa Therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Grant Or Contract) with Isa Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Alpine Immune Sciences;.
has a financial relationship (Professional Services) with Catalyst Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Beyond Spring Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with ALX Oncology ;.
has a financial relationship (Grant Or Contract) with Jounce Therapeutics;.

Umang Swami, MD, MS

has a financial relationship (Other) with Seattle Genetics;.
has a financial relationship (Other) with AstraZeneca ;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Sanofi ;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with ImVax;.
has a financial relationship (Other) with Gilead;.

Mei Wei, MD

has a financial relationship (Other) with Gilead Science;.
Case Presenter(s)

vyshak Alva Venur

has no relevant financial relationships to disclose at this time.

Anna Chalmers

has a financial relationship (Independent contractor) with Exactech;.
has a financial relationship (Independent contractor) with Springwork Therapeutics;.
has a financial relationship (Grant Or Contract) with boehringer ingelheim;.
has a financial relationship (Grant Or Contract) with Adaptimmune;.
has a financial relationship (Grant Or Contract) with GSK;.

Nicholas Gorden

has no relevant financial relationships to disclose at this time.

Wesley Jones, DO

has no relevant financial relationships to disclose at this time.

Katie Kerrigan, DO

has a financial relationship (Independent contractor) with Quality Fieldwork Associates;.
has a financial relationship (Independent contractor) with GLG consulting group;.
has a financial relationship (Independent contractor) with Knowledge Gate Group;.

Vinay Mathew Thomas

has no relevant financial relationships to disclose at this time.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity is supported with an independent Medical Education Grant from AstraZeneca.

Available Credit

  • 10.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.